Glaxosmithkline Cons Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GLAXOSMITHKLINE CONS, and what generic alternatives to GLAXOSMITHKLINE CONS drugs are available?
GLAXOSMITHKLINE CONS has thirteen approved drugs.
There are five US patents protecting GLAXOSMITHKLINE CONS drugs.
There are one hundred and nine patent family members on GLAXOSMITHKLINE CONS drugs in twenty-three countries and thirteen supplementary protection certificates in six countries.
Summary for Glaxosmithkline Cons
International Patents: | 109 |
US Patents: | 5 |
Tradenames: | 10 |
Ingredients: | 9 |
NDAs: | 13 |
PTAB Cases with Glaxosmithkline Cons as petitioner: | See PTAB cases with Glaxosmithkline Cons as petitioner |
Drugs and US Patents for Glaxosmithkline Cons
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline Cons | LAMISIL AT | terbinafine | GEL;TOPICAL | 021958-001 | Jul 24, 2006 | OTC | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | OTC | Yes | Yes | 9,320,862 | See Plans and Pricing | Y | See Plans and Pricing | |||
Glaxosmithkline Cons | ALLI | orlistat | CAPSULE;ORAL | 021887-001 | Feb 7, 2007 | OTC | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
Glaxosmithkline Cons | VOLTAREN ARTHRITIS PAIN | diclofenac sodium | GEL;TOPICAL | 022122-001 | Oct 17, 2007 | OTC | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | OTC | Yes | Yes | 8,062,264 | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Glaxosmithkline Cons
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline Cons | LAMISIL AT | terbinafine | GEL;TOPICAL | 021958-001 | Jul 24, 2006 | 5,681,849*PED | See Plans and Pricing |
Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | 7,101,866 | See Plans and Pricing |
Glaxosmithkline Cons | LAMISIL AT | terbinafine hydrochloride | SOLUTION;TOPICAL | 021124-001 | Mar 17, 2000 | 4,680,291 | See Plans and Pricing |
Glaxosmithkline Cons | LAMISIL | terbinafine | GEL;TOPICAL | 020846-001 | Apr 29, 1998 | 4,680,291 | See Plans and Pricing |
Glaxosmithkline Cons | LAMISIL AT | terbinafine hydrochloride | SOLUTION;TOPICAL | 021124-001 | Mar 17, 2000 | 6,121,314*PED | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GLAXOSMITHKLINE CONS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 60 mg | ➤ Subscribe | 2010-09-08 |
➤ Subscribe | Gum | 4 mg | ➤ Subscribe | 2013-01-22 |
➤ Subscribe | Gum | 2 mg | ➤ Subscribe | 2013-01-22 |
International Patents for Glaxosmithkline Cons Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Norway | 338929 | See Plans and Pricing |
South Africa | 200708545 | See Plans and Pricing |
European Patent Office | 1525017 | See Plans and Pricing |
Poland | 1868731 | See Plans and Pricing |
China | 1930054 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Glaxosmithkline Cons Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0024587 | 93C0136 | Belgium | See Plans and Pricing | PRODUCT NAME: TERBINAFINE (250 MG) SOUS FORME DE CHLORHYDRATE (281,25 MG); NAT. REG.: 616 S 201 F3 19911031; FIRST REG.: GB PL 0101/0304 19901003 |
0129748 | SPC/GB98/044 | United Kingdom | See Plans and Pricing | PRODUCT NAME: ORLISTAT; REGISTERED: UK EU/1/98/071/001 19980729; UK EU/1/98/071/002 19980729; UK EU/1/98/071/003 19980729; UK EO/1/98/071/004 19980729; UK EU/1/98/071/005 19980729; UK EU/1/98/071/006 19980729 |
1305329 | 08C0014 | France | See Plans and Pricing | PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111 |
2506844 | 132018000000341 | Italy | See Plans and Pricing | PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117 |
1519731 | 13C0067 | France | See Plans and Pricing | PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.